Table 1

Predicted lornoxicam/(S)-warfarin interactions

	LNX (inhibitor)	(S)-Warfarin (substrate)	(S)-Warfarin (inhibitor)	LNX (substrate)
Therapeutic concentration (μM)	[I] = 3^1-a	[S] = 0.017^1-b	[I] = 0.017^1-b	[S] = 3^1-a
K _m (μM)		4^1-c		4^1-d
K _i (μM)	4^1-d		4^1-c
f _h		1^1-e		1^1-a
f _m		0.85^1-f		0.9^1-a
[I]/K _i	0.75		0.0004
Percent inhibition	43		0.24
R	0.57		1
R _c	1.58		1
R _observed	1.32 for rac^1-g		?^1-h

Drug/drug interactions were predicted as described in the text. The therapeutic concentration describes the concentration expected in the cytosol of the hepatocyte under therapeutic conditions. These values were derived as described in the text. Percent inhibition,R, and R_c were calculated as described in the text. R_observed indicates the degree of change in AUC_SS or C_SS in a clinical interaction study.

↵1-a Skjodt and Davies, 1998.
↵1-b Chan et al., 1994.
↵1-c He et al., 1995.
↵1-d Bonnabry et al., 1996.
↵1-e Hermans and Thijssen, 1993.
↵1-f Miners and Birkett, 1998.
↵1-g Ravic et al., 1990.
↵1-h No clinical data available.